HN Logo
Prior Authorization Protocol
NUVESSATM (metronidazole vaginal gel 1.3%)
NATL
Coverage of drugs is first determined by the member’s pharmacy or medical benefit. Please consult with or refer to the Evidence of Coverage document.
  1. FDA Approved Indications:
    • For the treatment of bacterial vaginosis in non-pregnant women
  2. Health Net Approved Indications and Usage Guidelines:
    • For the treatment of bacterial vaginosis in non-pregnant women
    AND
    • Failure or clinically significant adverse effects to metronidazole gel 0.75% (generic MetroGel-Vaginal, Vandazole)
  3. Coverage is Not Authorized For:
    • Non-FDA approved indications, which are not listed in the Health Net Approved Indications and Usage Guidelines section, unless there is sufficient documentation of efficacy and safety in the published literature.
  4. General Information:
    This field intentionally left blank.
  5. Therapeutic Alternatives:
    Drug Dosing Regimen Dose Limit/ Maximum Dose

    metronidazole gel 0.75% (MetroGel-Vaginal, Vandazole)

    One applicatorful (~37.5 mg) intravaginally QD to BID for 5 days

    This field intentionally left blank

    * Requires Prior Authorization
  6. Recommended Dosing Regimen and Authorization Limit:
    Drug Dosing Regimen Authorization Limit

    Nuvessa

    One applicator (~65 mg) administered intravaginally as a single dose at bedtime

    Length of Benefit

  7. Product Availability:
    Pre-filled applicator containing vaginal gel (1.3%): 65 mg metronidazole in 5 grams of gel
  8. References:
    1. Nuvessa [prescribing information]. Actavis Pharma Inc. Parsippany, NJ; January 2015.
    2. Lexicomp OnlineR , Lexi-DrugsR , Hudson, Ohio: Lexi-Comp, Inc.; accessed November 2015.
The material provided to you are guidelines used by this plan to authorize, modify or determine coverage for persons with similar illnesses or conditions. Specific care and treatment may vary depending on individual need and the benefits covered under your contract.